Albert Reising

1.0k total citations
18 papers, 591 citations indexed

About

Albert Reising is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Albert Reising has authored 18 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Albert Reising's work include Renal cell carcinoma treatment (7 papers), Advanced Breast Cancer Therapies (4 papers) and Renal and related cancers (4 papers). Albert Reising is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Advanced Breast Cancer Therapies (4 papers) and Renal and related cancers (4 papers). Albert Reising collaborates with scholars based in United States, Germany and Switzerland. Albert Reising's co-authors include Martin H. Voss, Parul Patel, A. Ari Hakimi, Robert J. Motzer, Timothy A. Chan, Fengshen Kuo, Mahtab Marker, Yuan Cheng, Irina Ostrovnaya and Lynda Vuong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Albert Reising

18 papers receiving 582 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albert Reising United States	8	359	250	239	193	101	18	591
Taro Ohba Japan	14	342 1.0×	286 1.1×	333 1.4×	151 0.8×	55 0.5×	23	697
Hidenori Kouso Japan	11	250 0.7×	223 0.9×	234 1.0×	87 0.5×	34 0.3×	25	508
Gabriel Olmedilla Spain	12	239 0.7×	237 0.9×	125 0.5×	132 0.7×	42 0.4×	17	556
Eva Regina Haspinger Italy	8	128 0.4×	120 0.5×	151 0.6×	60 0.3×	121 1.2×	13	403
Shuchen Lin China	11	170 0.5×	245 1.0×	156 0.7×	168 0.9×	34 0.3×	26	494
Helin Feng China	15	144 0.4×	238 1.0×	130 0.5×	197 1.0×	94 0.9×	47	557
Caroline Archer United Kingdom	11	159 0.4×	124 0.5×	244 1.0×	99 0.5×	20 0.2×	21	522
Junling Zhang China	14	167 0.5×	216 0.9×	221 0.9×	129 0.7×	29 0.3×	56	567
Chun‐Chieh Wu Taiwan	12	171 0.5×	187 0.7×	200 0.8×	87 0.5×	19 0.2×	32	466
Cheng Tang China	15	158 0.4×	196 0.8×	164 0.7×	117 0.6×	47 0.5×	40	516

Countries citing papers authored by Albert Reising

Since Specialization

Citations

This map shows the geographic impact of Albert Reising's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Reising with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Reising more than expected).

Fields of papers citing papers by Albert Reising

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Reising. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Reising. The network helps show where Albert Reising may publish in the future.

Co-authorship network of co-authors of Albert Reising

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Reising. A scholar is included among the top collaborators of Albert Reising based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Reising. Albert Reising is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Laurentiis, Michelino De, Luís Costa, Joseph Gligorov, et al.. (2022). EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. Journal of Clinical Oncology. 40(16_suppl). TPS1109–TPS1109. 7 indexed citations

Juric, Dejan, Hope S. Rugo, Albert Reising, et al.. (2022). Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. Journal of Clinical Oncology. 40(16_suppl). 1006–1006. 4 indexed citations

Chowdhury, Simon, J. Infante, Robert D. Hawkins, et al.. (2021). A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 19(5). 434–446. 19 indexed citations

Ciruelos, Eva, Sibylle Loibl, Ingrid A. Mayer, et al.. (2021). Abstract PD2-06: Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study. Cancer Research. 81(4_Supplement). PD2–6. 7 indexed citations

Juric, Dejan, Fabrice André, Christian F. Singer, et al.. (2020). Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study. Cancer Research. 80(4_Supplement). P4–10. 6 indexed citations

Hakimi, A. Ari, Martin H. Voss, Fengshen Kuo, et al.. (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery. 9(4). 510–525. 156 indexed citations

Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. 21(2). 283–293. 127 indexed citations

Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma. SSRN Electronic Journal. 1 indexed citations

Voss, Martin H., Albert Reising, Yuan Cheng, et al.. (2018). Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. The Lancet Oncology. 19(12). 1688–1698. 107 indexed citations

10.

Voss, Martin H., David Chen, Albert Reising, et al.. (2018). PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clinical Cancer Research. 25(2). 506–514. 29 indexed citations

11.

Yao, James C., Jonathan Strosberg, Nicola Fazio, et al.. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Annals of Oncology. 29. viii467–viii468. 55 indexed citations

12.

Voss, Martin H., Yuan Cheng, Mahtab Marker, et al.. (2018). Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 36(6_suppl). 639–639. 3 indexed citations

13.

McLean, Lee Anne, Chiara Buono, Pierre Moulin, et al.. (2011). The Use of Rat Lens Explant Cultures to Study the Mechanism of Drug-Induced Cataractogenesis. Toxicological Sciences. 126(1). 128–139. 6 indexed citations

14.

Blumenthal, Rosalyn D., et al.. (2002). Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines.. PubMed. 8(5). 1301–9. 11 indexed citations

15.

Blumenthal, Rosalyn D., et al.. (2000). Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. International Journal of Cancer. 86(2). 276–280. 44 indexed citations

16.

Blumenthal, Rosalyn D., et al.. (2000). Effect of tumor producing cytokines on bone marrow proliferation. Experimental Hematology. 28(7). 50–50. 1 indexed citations

17.

Blumenthal, Rosalyn D., et al.. (2000). Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. International Journal of Cancer. 86(2). 276–276. 3 indexed citations

18.

Blumenthal, Rosalyn D., et al.. (1999). Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model. European Journal of Cancer. 35(5). 815–824. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact